Ildong Pharmaceutical

Ildong Pharmaceutical, founded in 1941, is a prominent South Korean entity within the Pharmaceuticals and Healthcare sectors, operating under the ticker KRX: 249420. With a history spanning 78 years, the Ildong brand has cultivated a strong reputation for delivering high-quality service and a diverse portfolio of prescription (ETC) and over-the-counter (OTC) products. The company's strategic vision is to evolve into an innovative, R&D-driven pharmaceutical enterprise focused on developing novel therapeutic options for diseases with significant unmet medical needs. Its core R&D endeavors are concentrated in critical therapeutic areas including oncology, immune-oncology, endocrinology, liver fibrosis, and neurology, reflecting a commitment to advancing medical science and patient care. The company employs between 1,000-5,000 employees and reported revenue of $436.2M.

The operational footprint of Ildong Pharmaceutical is characterized by its dedication to research and development, aiming to address complex health challenges. This focus is supported by a robust internal structure, and the company invites further exploration by stating: Meet Ildong Pharmaceutical's team to understand the leadership and expertise driving its innovation. The company's product range includes pharmaceuticals, with a strong emphasis on quality and efficacy, serving both healthcare professionals and consumers across its market. Its strategic direction prioritizes scientific advancement and the creation of new treatment modalities.

Ildong Pharmaceutical's market presence is primarily within South Korea, with a single primary location in Seoul, Asia. The company's long-standing history and established brand recognition in the local healthcare market underscore its stability and influence. While specific financial details are not directly linked, the company's revenue indicates substantialView more...